184 related articles for article (PubMed ID: 10733518)
1. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Akiba H; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 2000 Apr; 95(7):2434-9. PubMed ID: 10733518
[TBL] [Abstract][Full Text] [Related]
2. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
[TBL] [Abstract][Full Text] [Related]
3. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo.
Yuan X; Salama AD; Dong V; Schmitt I; Najafian N; Chandraker A; Akiba H; Yagita H; Sayegh MH
J Immunol; 2003 Mar; 170(6):2949-55. PubMed ID: 12626546
[TBL] [Abstract][Full Text] [Related]
4. CD27/CD70, CD134/CD134 ligand, and CD30/CD153 pathways are independently essential for generation of regulatory cells after intratracheal delivery of alloantigen.
Aramaki O; Shirasugi N; Akiyama Y; Shibutani S; Takayama T; Shimazu M; Kitajima M; Ikeda Y; Okumura K; Yagita H; Niimi M
Transplantation; 2003 Sep; 76(5):772-6. PubMed ID: 14501851
[TBL] [Abstract][Full Text] [Related]
5. Association of the CD134/CD134L costimulatory pathway with acute rejection of small bowel allograft.
Tian L; Guo W; Yuan Z; Lui VC; Chan JK; Yagita H; Akiba H; Dallman M; Tam PK
Transplantation; 2002 Jul; 74(1):133-8. PubMed ID: 12134113
[TBL] [Abstract][Full Text] [Related]
6. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease.
Lamb LS; Abhyankar SA; Hazlett L; O'Neal W; Folk RS; Vogt S; Parrish RS; Bridges K; Henslee-Downey PJ; Gee AP
Cytometry; 1999 Oct; 38(5):238-43. PubMed ID: 10516610
[TBL] [Abstract][Full Text] [Related]
8. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
[TBL] [Abstract][Full Text] [Related]
10. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
Valzasina B; Guiducci C; Dislich H; Killeen N; Weinberg AD; Colombo MP
Blood; 2005 Apr; 105(7):2845-51. PubMed ID: 15591118
[TBL] [Abstract][Full Text] [Related]
11. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
12. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
13. Normal IgG protects against acute graft-versus-host disease by targeting CD4(+)CD134(+) donor alloreactive T cells.
Caccavelli L; Field AC; Betin V; Dreillard L; Belair MF; Bloch MF; Bruneval P; Kazatchkine M; Bellon B
Eur J Immunol; 2001 Sep; 31(9):2781-90. PubMed ID: 11536177
[TBL] [Abstract][Full Text] [Related]
14. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses.
Morimoto S; Kanno Y; Tanaka Y; Tokano Y; Hashimoto H; Jacquot S; Morimoto C; Schlossman SF; Yagita H; Okumura K; Kobata T
J Immunol; 2000 Apr; 164(8):4097-104. PubMed ID: 10754303
[TBL] [Abstract][Full Text] [Related]
15. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
Drobyski WR; Majewski D
Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
[TBL] [Abstract][Full Text] [Related]
16. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
[TBL] [Abstract][Full Text] [Related]
17. Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases.
Nozawa K; Ohata J; Sakurai J; Hashimoto H; Miyajima H; Yagita H; Okumura K; Azuma M
J Immunol; 2001 Nov; 167(9):4981-6. PubMed ID: 11673505
[TBL] [Abstract][Full Text] [Related]
18. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
Zhao J; Zhao XY; Huang XJ
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
[TBL] [Abstract][Full Text] [Related]
19. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
[TBL] [Abstract][Full Text] [Related]
20. CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease.
Streeter PR; Zhang X; Tittle TV; Schön CN; Weinberg AD; Maziarz RT
Biol Blood Marrow Transplant; 2004 May; 10(5):298-309. PubMed ID: 15111929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
